COVID-19 PandemicCOVID-19NCT05125874
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A study testing Recombinant SARS-CoV-2 Fusion Protein Vaccine in people with COVID-19 Pandemic, run by Livzon Pharmaceutical Group Inc. at 1 site in China.
Trial summary
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- COVID-19 Pandemic
- What is being tested?
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Type of treatment
- Vaccines, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 45 participants
- Where
- 1 siteChina
- Study dates
- 30 Sep 2021to 30 Sep 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants aged 18 years and older who have completed the second dose of 2-dose regimen of inactive vaccination (Vero cell) against SARS-CoV-2 in the past 3-6 months;
- Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
- In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
- Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.
Who cannot join
- Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR.
- History of previous COVID-19 infection.
- Fever is suspected or diagnosed within 72 hours before enrollment, or the axillary body temperature ≥37.3℃ on the day of enrollment.
- History of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of V-01.
- People who currently suffer from the following diseases:
- Symptoms related to acute respiratory infections (such as: sneezing, nasal congestion, runny nose, cough, sore throat, loss of taste, chills, shortness of breath, etc.)
Show all 16Show fewer
- Patients with thrombocytopenia, any coagulation dysfunction, or receive anticoagulant treatment, etc.
- Patients with congenital or acquired angioedema/neuroedema;
- A history of congenital or acquired immunodeficiency or autoimmune disease (except for mild psoriasis, controllable autoimmune thyroid disease, vitiligo, or stable celiac disease that does not require immunosuppressive or immunomodulatory therapy); no spleen , or history of spleen surgery, history of trauma, or treatment with immunomodulators within 6 months, such as: glucocorticoid with the dose causing immunosuppressive (dose reference: equivalent to prednisone 20mg/day, more than one week); or monoclonal antibody ; or thymosin; or interferon, etc.; but local medication (such as ointment, eye drops, inhalation or nasal spray) is allowed.
- Patients with active tuberculosis, viral hepatitis, human immunodeficiency virus or syphilis infection.
- Patients with acute diseases, or acute attacks of chronic diseases, or uncontrolled severe chronic diseases: history of chronic respiratory diseases (including moderate to severe asthma, COPD, pulmonary fibrosis), hypertension that cannot be controlled by drugs (systolic blood pressure ≥150mmHg) And/or diastolic blood pressure ≥100mmHg), history of severe cardiovascular disease (including heart failure, coronary artery disease, cardiomyopathy), history of chronic kidney disease, history of cancer (except for basal cell carcinoma), diabetes (unsatisfied blood sugar control or diabetes related serious complications).
- Received attenuated live vaccine within 28 days before the vaccination or any subunit vaccines and inactivated vaccines within 14 days before the vaccination.
- Injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; or with the plan to use such product within 6 month after immunization.
- Pregnant (including positive urine pregnancy test for women of childbearing age) or breastfeeding women. Or women or their partners who have a pregnancy plan within 3 months after the trial vaccination.
- Have participated in or are participating in other COVID-19 related clinical trials, or are participating in other drug clinical trials;
- Those considered by the investigator as inappropriate to participate in the study.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Read the detailed description
This is a single arm, open-label clinical study. 45 participants aged 18 years and older who have completed the 2 doses of administration of inactive vaccines will be enrolled in this study to evaluate the safety and immunogenicity of V-01.
The participants will be collected blood before immunization, on day 7, day 14, day 28 and 6 month to evaluate humoral immunity.
All adverse events (AEs) within 30 minutes and 0-7 days after booster immunization, and unsolicited AEs from 8 to 28 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization will be collected from all participants.
- Conditions
- COVID-19 Pandemic
- Being tested
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Keywords
- V-01 Booster
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Recombinant SARS-CoV-2 Fusion Protein VaccineBiological
Also called V-01
The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection.
| Study group | Role | What they receive |
|---|---|---|
| V-01 COVID-19 Vaccine | Experimental | One dose administrated by intramuscular injection Receives: Biological: Recombinant SARS-CoV-2 Fusion Protein Vaccine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Seroconvension of SARS-CoV-2 neutralizing antibodies
The seroconvension of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
Measured: 14 days and 28 days after booster immunization
GMT of SARS-CoV-2 neutralizing antibodies
The GMT of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
Measured: 14 days and 28 days after booster immunization
GMI of SARS-CoV-2 neutralizing antibodies
The GMI of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
Measured: 14 days and 28 days after booster immunization
Secondary outcomes (8)
GMT of SARS-CoV-2 (wild type) neutralizing antibodies
GMT of SARS-CoV-2 (wild type) neutralizing antibodies before and on day 7 after booster immunization
Measured: Before and on day 7 after booster immunization
Seroconvension of SARS-CoV-2 (wild type) neutralizing antibodies
The seroconvension of SARS-CoV-2 (wild type) neutralizing antibodies on day 7 after booster immunization
Measured: On day 7 after booster immunization
GMI of SARS-CoV-2 (wild type) neutralizing antibodies
The GMI of SARS-CoV-2 (wild type) neutralizing antibodies on day 7 after booster immunization
Measured: On day 7 after booster immunization
GMT of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies
The GMT of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies before and on day 7, day 14, day 28 after booster immunization
Measured: Before and on day 7, day 14, day 28 after booster immunization
Seroconvension of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies
The seroconvension of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies on day 7, day 14, day 28 after booster immunization
Measured: On day 7, day 14, day 28 after booster immunization
GMI of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies
The GMI of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies on day 7, day 14, day 28 after booster immunization
Measured: On day 7, day 14, day 28 after booster immunization
Long-term immunity
The seroconvension, GMT and GMI of SARS-CoV-2 (wild type) and SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies after 6 months after booster immunization
Measured: 6 months after booster immunization
Incidence of AEs
The incidence of adverse events (AEs) occur within 30 minutes, 0-7 days, 8-28 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization.
Measured: 30 minutes, 0-7 days, 8-28 days after booster immunization, 12 months after booster immunization.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Nov 2021
- Study start30 Sep 2021
- Primary completion30 Aug 2023 (estimated)
- Study completion30 Sep 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for COVID-19 PandemicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 45 participants (actual)
Sponsor and investigators
- Lead sponsor
- Livzon Pharmaceutical Group Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Ligong Lu, Dr., Principal investigator, Zhuhai People's Hospital Medical Group
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05125874
- Sponsor's protocol ID
- ICV-V-01-Booster
- Acronym
- COVID-19
- Status last verified
- Nov 2021
- First submitted
- 9 Nov 2021
- Last updated
- 18 Nov 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Nov 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
- ClinicalTrials.gov ID
- NCT05125874
- Acronym / sponsor ID
- COVID-19 / ICV-V-01-Booster
- Conditions
- COVID-19 Pandemic
- Keywords
- V-01 Booster
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 45 participants (actual)
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry (pharma, biotech, devices)
- Study start
- 30 Sep 2021 (actual)
- Primary completion
- 30 Aug 2023 (estimated)
- Study completion
- 30 Sep 2023 (estimated)
- First posted
- 18 Nov 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of Inactivated Vaccines
Detailed description
This is a single arm, open-label clinical study. 45 participants aged 18 years and older who have completed the 2 doses of administration of inactive vaccines will be enrolled in this study to evaluate the safety and immunogenicity of V-01.
The participants will be collected blood before immunization, on day 7, day 14, day 28 and 6 month to evaluate humoral immunity.
All adverse events (AEs) within 30 minutes and 0-7 days after booster immunization, and unsolicited AEs from 8 to 28 days after booster immunization, as well as SAEs and AESIs from the first vaccination to 12 months after booster immunization will be collected from all participants.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| V-01 COVID-19 Vaccine | Experimental | Biological: Recombinant SARS-CoV-2 Fusion Protein VaccineOne dose administrated by intramuscular injection |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Participants aged 18 years and older who have completed the second dose of 2-dose regimen of inactive vaccination (Vero cell) against SARS-CoV-2 in the past 3-6 months;
- Voluntarily participate in the study and sign the informed consent form, who can provide valid ID and follow the study protocol requirement;
- In the past 14 days, no history of high or medium risk of the epidemic, overseas travel history or residence history; no history of contact with confirmed, asymptomatic or suspected COVID-19 cases; no history of contact with the persons from high- and medium-risk epidemic areas or contact patients with fever or respiratory symptoms; and those who are not in isolation period.
- Males of reproductive potential and females of childbearing potential voluntarily agree to take effective and acceptable contraceptive methods from the signing of informed consent form to 3 months after vaccination.
Key exclusion criteria (16 listed)
- Confirmed COVID-19 cases, or positive for SARS-CoV-2 test by RT-PCR.
- History of previous COVID-19 infection.
- Fever is suspected or diagnosed within 72 hours before enrollment, or the axillary body temperature ≥37.3℃ on the day of enrollment.
- History of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of V-01.
- People who currently suffer from the following diseases:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Recombinant SARS-CoV-2 Fusion Protein VaccineAlso: V-01The product should be a milky-white suspension for injection. For prevention of SARS-CoV-2 infection. | Biological | V-01 COVID-19 Vaccine |
Primary outcome
Seroconvension of SARS-CoV-2 neutralizing antibodies
Time frame: 14 days and 28 days after booster immunization
The seroconvension of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
GMT of SARS-CoV-2 neutralizing antibodies
Time frame: 14 days and 28 days after booster immunization
The GMT of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
GMI of SARS-CoV-2 neutralizing antibodies
Time frame: 14 days and 28 days after booster immunization
The GMI of SARS-CoV-2 neutralizing antibodies on 14 days and 28 days after booster immunization
8 secondary outcomes
GMT of SARS-CoV-2 (wild type) neutralizing antibodies
Time frame: Before and on day 7 after booster immunization
Seroconvension of SARS-CoV-2 (wild type) neutralizing antibodies
Time frame: On day 7 after booster immunization
GMI of SARS-CoV-2 (wild type) neutralizing antibodies
Time frame: On day 7 after booster immunization
GMT of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies
Time frame: Before and on day 7, day 14, day 28 after booster immunization
Seroconvension of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies
Time frame: On day 7, day 14, day 28 after booster immunization
GMI of SARS-CoV-2 delta variant (B1.617.2) neutralizing antibodies
Time frame: On day 7, day 14, day 28 after booster immunization
Long-term immunity
Time frame: 6 months after booster immunization
Incidence of AEs
Time frame: 30 minutes, 0-7 days, 8-28 days after booster immunization, 12 months after booster immunization.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Nov 2021.
Related trials for COVID-19 Pandemic
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
RecruitingPhase 3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Respiratory Tract Diseases, Influenza (Pandemic)
Enrolling by invitationObservational study
Prescribing Trends and Associated Outcomes of Antiepileptic Drugs in US Nursing Homes Surrounding the COVID-19 Pandemic
Dementia
Active, not recruitingObservational study
Vaccine Responses to SARS-CoV-2 and Other Emerging Infectious Diseases
COVID-19, Vaccination
Active, not recruiting
Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
Liver Diseases, Alcohol Use Disorder
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ligong Lu, Dr. principal investigator
Zhuhai People's Hospital Medical Group
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Recombinant SARS-CoV-2 Fusion Protein Vaccine in people with COVID-19 Pandemic, run by Livzon Pharmaceutical Group Inc. at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Seroconvension of SARS-CoV-2 neutralizing antibodies (time frame: 14 days and 28 days after booster immunization). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Nov 2021.